Related Experiment Videos
Management of patients with hypertension and angina pectoris
Insights
Managing hypertension and angina requires understanding heart remodeling. Combined beta blockers and calcium antagonists effectively lower blood pressure and improve coronary blood flow in these patients.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Hypertension leads to cardiac remodeling, including left ventricular hypertrophy, increased diastolic pressure, and reduced coronary vascular reserve.
- This remodeling, coupled with potential coronary atherosclerosis, complicates the management of angina pectoris in hypertensive patients.
- Understanding the specific cardiac status (e.g., ventricular size, function, coronary patency) is crucial for effective treatment.
Purpose of the Study:
- To outline a strategic approach for managing patients with concurrent hypertension and angina pectoris.
- To highlight the importance of considering cardiac pathophysiology and ventricular status in therapeutic decisions.
- To evaluate the efficacy of different anti-ischemic and antihypertensive regimens based on patient-specific cardiac conditions.
Main Methods:
- Review of the pathophysiology of hypertensive heart disease and its impact on coronary circulation.
- Analysis of therapeutic options, including diuretics, nitrates, digitalis, beta-blockers, and calcium antagonists.
- Consideration of left ventricular structure and function (hypertrophic, dilated, hyperdynamic, decompensated) in drug selection.
Main Results:
- Combined therapy with beta-blockers and calcium antagonists demonstrates significant efficacy in lowering blood pressure and enhancing coronary blood flow.
- Specific calcium channel blockers (e.g., nifedipine, nitrendipine) are suitable for patients with decompensated ventricular function due to minimal negative inotropic effects.
- Agents like verapamil, with direct negative inotropic effects, require careful consideration in patients with compromised ventricular function.
Conclusions:
- Tailoring anti-ischemic and antihypertensive therapy to individual patient cardiac status is paramount.
- The combination of beta-blockers and calcium antagonists offers a potent and beneficial treatment strategy for hypertension with angina.
- Further determination of specific agent roles in the natural history of hypertensive heart disease is warranted.
Abstract:
Management of patients with concomitant hypertension and angina pectoris mandates that the physician pay attention to the underlying pathophysiology. The heart, when exposed to years of hypertension, becomes "remodeled." Overall mass is enlarged, the walls are thickened, and initial cavity volume remains normal or relatively small. Left ventricular end-diastolic pressure rises in the setting of a hypertrophic noncompliant ventricle; coronary resistance and coronary perfusion pressure are increased; and coronary vascular reserve, even with widely patent coronary arteries, is decreased. Long-standing hypertension--a risk factor for coronary atherosclerosis--is often accompanied by epicardial coronary stenoses that aggravate these coronary abnormalities. In managing the patient with hypertension and angina pectoris, it is important to determine whether the angina occurs in the setting of hypertensive hypertrophic disease alone or coexists with coronary arterial stenoses. Also important to therapy is whether the ventricle is of normal size with good function or decompensated with dilatation and diminished function. The latter two anatomic considerations, namely, epicardial coronary patency and left ventricular cavity size, will influence the choice of an anti-ischemic regimen. For example, diuretic and nitrate therapy can be hazardous, and digitalis unnecessary, in the setting of a nondilated hypertrophic ventricle with hyperdynamic function. On the other hand, the combined use of beta blocking agents plus calcium antagonists is particularly effective in lowering blood pressure and in improving coronary blood flow. Finally, this combination has been shown to be rapidly effective and to have prolonged benefit in this setting. The choice of these latter agents is also affected by the underlying state of the ventricle. Calcium channel blocking agents without significant negative inotropic effect, such as nifedipine and nitrendipine, would be suitable in patients with decompensated ventricular function and dilated left ventricular cavities. Both of these drugs have been shown to increase cardiac output and contractility via a reflex effect and to have little or no direct negative inotropic effect. In contrast, verapamil has a direct negative inotropic effect. The final choice of agents must be tailored to the needs of the individual patient, and the physician also has to determine the role of specific agents in the natural history of hypertensive heart disease.